Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.81 |
| ▸ | CDK1 | P06493 | 8/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CCND1 | P24385 | 1/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.58 |
| ▸ | CCND3 | P30281 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | CDK7 | P50613 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | CCNH | P51946 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448451 | 0.96 | CDK2 (0.86) | CDK2CDK1KCNH2CCNT1CDK4 | |
| SCHEMBL1447698 | 0.91 | CDK2 (0.93) | CDK2CDK1KCNH2CCNT1CDK4 | |
| SCHEMBL1448230 | 0.89 | CDK2 (1.00) | CDK2CDK1KCNH2CCNT1CDK4 | |
| SCHEMBL1448597 | 0.88 | CDK2 (0.66) | CDK2CDK1KCNH2 | |
| SCHEMBL1447207 | 0.88 | CDK2 (0.68) | CDK2CDK1KCNH2CDK4CCND1 | |
| SCHEMBL1447718 | 0.87 | CDK2 (0.77) | CDK2CDK1KCNH2CCNT1CDK4 | |
| SCHEMBL1447731 | 0.87 | CDK2 (0.82) | CDK2CDK1KCNH2CCNT1CDK4 | |
| SCHEMBL1447392 | 0.87 | CDK2 (0.82) | CDK2CDK1KCNH2CCNT1CDK4 | |
| SCHEMBL1447874 | 0.86 | CDK2 (0.81) | CDK2CDK1KCNH2CCNT1CDK4 | |
| SCHEMBL1447954 | 0.86 | CDK2 (0.80) | CDK2CDK1KCNH2CCNT1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | claimed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| EP-1912974-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | claimed |
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1912974-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | CDK2 13/4885CDK1 35/4885KCNH2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.